A 2-stage phase II design with direct assignment option in stage II for initial marker validation

Clinical Cancer Research

Volumn 18, Issue 16, 2012, Pages 4225-4233

  An, Ming Wen ^a   Mandrekar, Sumithra J ^b   Sargent, Daniel J ^b  

^a VASSAR COLLEGE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER STAGING; CLINICAL DECISION MAKING; CLINICAL RESEARCH; EXPERIMENTAL DESIGN; HUMAN; INTERMETHOD COMPARISON; PATIENT IDENTIFICATION; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; SENSITIVITY ANALYSIS; STUDY DESIGN; SYSTEMATIC ERROR; TREATMENT OUTCOME; TREATMENT PLANNING; VALIDATION PROCESS;

CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 84865080246     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0686     Document Type: Article

References (13)

1. Mandrekar SM, Grothey A, Goetz MP, Sargent DJ. Clinical trial designs for prospective validation. Am J Pharmacogenomics 2005;5:317-25.
2. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7.
3. Simon R, Wang SJ. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J 2006;6:166-73.
4. Wang SJ, O'Neill RT, Hung HMJ. Approaches to evaluation of treatment effect in RCT with genomic subset. Pharm Stat 2007;6:227-44.
5. Lee JJ, Gu X, Liu S. Bayesian adaptive randomization designs for targeted agent development. Clin Trials 2010;7:584-96.
6. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004;10:6759-63.
7. Smit EF, Dingemans AC, Thunnissen FB, Hochstenbach MM, van Suylen R-J, Postmus PE. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-Ras mutations a brief report. J Thoracic Oncol 2010;5:719-20.
8. Mellema WW, Dingemans AMC, Groen HJM, van Wijk A, Burgers S, Kunst PWA, et al. A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with KRAS mutation. In: Proceedings of the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine; 2012 Jan 8-11; San Diego, CA. Philadelphia (PA): AACR; 2012. Abstract nr PR-5.
9. Acquaviva J, Smith D, Sang J, Wada Y, Proia DA. Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib [abstract]. In: Proceedings of the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine; 2012 Jan 8-11; San Diego, CA. Philadelphia (PA): AACR; 2012. Abstract nr B1.
10. Colton T. A model for selecting one of two medical treatments. J Am Stat Assoc 1963;58:388-400.
11. Colton T. A two-stage model for selecting one of two treatments. Biometrics 1965;21:169-180.
12. Avis NE, Smith KW, Link CL, Hortobagyi GN, Rivera E. Factors associated with participation in breast cancer treatment clinical trials. J Clin Oncol 2006;24:1860-7.
13. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.